Cartesian Therapeutics, Inc. (RNAC) — Financial statements
Income statement, balance sheet, and cash flow for Cartesian Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3↓92.8% | 39↑49.6% | 26↓76.5% | 111↑30.2% | 85 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00↓100.0% | 2 | 0.00 | |
| Gross Profit | 3↓92.8% | 39↑49.6% | 26↓76.1% | 109↑27.8% | 85 | |
| Operating Expenses | ||||||
| R&D Expenses | 58↑28.7% | 45↓36.7% | 71↓1.5% | 72↑5.3% | 69 | |
| General & Administrative Expenses | 31↑4.5% | 30↓25.5% | 40↑69.5% | 24↑14.0% | 21 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 31↑4.5% | 30↓25.5% | 40↑69.5% | 24↑14.0% | 21 | |
| Other Expenses | 0.00↓100.0% | 8↑967.5% | 0.71↑134.9% | -2 | 0.00 | |
| Operating Expenses | 90↑8.1% | 83↓26.3% | 112↑19.3% | 94↑5.0% | 90 | |
| Total Costs & Expenses | 90↑8.1% | 83↓26.3% | 112↑16.8% | 96↑7.3% | 90 | |
| Operating Results | ||||||
| Operating Income | -87↓97.5% | -44↑49.2% | -86↓694.4% | 15↑416.2% | -5 | |
| Depreciation & Amortization | 0.00↓100.0% | 1↑36.5% | 0.84↓58.6% | 2↑18.5% | 2 | |
| EBITDA | -87↓14.1% | -76↑67.7% | -235↓690.0% | 40↑872.4% | -5 | |
| EBIT | -87↓12.4% | -77↑67.3% | -236↓724.0% | 38↑649.7% | -7 | |
| Interest & Other Income | ||||||
| Net Interest Income | 7↓10.9% | 7↑246.6% | 2↑170.3% | -3↓6.6% | -3 | |
| Interest Income | 7↓10.9% | 7↑48.8% | 5 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00↓100.0% | 3↓6.5% | 3↑6.6% | 3 | |
| Non-Operating Income | 0.00↓100.0% | 33↓77.8% | 149↑742.5% | -23↓1120.3% | 2 | |
| Other Income / Expenses | -53↓58.8% | -33↑78.2% | -152↓852.7% | 20↑494.8% | -5 | |
| Income Before Tax | -139↓80.8% | -77↑67.7% | -239↓786.5% | 35↑457.7% | -10 | |
| Income Tax Expense | -9↓3303.1% | 0.29↑101.5% | -19↓3019.9% | -0.61↓103.8% | 16 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -130↓68.3% | -77↑64.8% | -220↓721.0% | 35↑237.7% | -26 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -130↓68.3% | -77↑64.8% | -220↓721.0% | 35↑237.7% | -26 | |
| Bottom-Line Net Income | -130↓67.3% | -78↑69.7% | -257↓1874.6% | 14↑156.4% | -26 | |
| EPS (Basic) | -5.02↓67.9% | -2.99↑94.0% | -49.76↓778.9% | 7.33↑208.8% | -6.74 | |
| EPS (Diluted) | -5.02↓52.6% | -3.29↑93.4% | -49.76↓1758.7% | 3.00↑145.5% | -6.60 | |
| Weighted Average Shares | 26↑0.3% | 26↑401.0% | 5↑28.6% | 4↑26.6% | 3 | |
| Weighted Average Diluted Shares | 26↑9.6% | 24↑358.2% | 5↑27.6% | 4↑27.6% | 3 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.